drugset / Trial / NCT06144671
GT201 Injection For The Treatment Of Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
Expected to complete 7 to 18 evaluable subjects (patients with advanced solid tumors),3 dose groups.A modified "3+3" dose-escalation design is utilized,This includes both accelerated dose escalation and traditional "3+3" dose escalation.The first dose group is accelerated titration,The first dose group is an accelerated titration of 1 to 6 evaluable subjects;The second and third dose groups are based on the traditional "3+3" dose-escalation principle,The second and third dose groups are based on the traditional "3+3" dose-escalation principle, with 3 to 6 evaluable subjects enrolled respectively.
Timeline
- Start
- 2023-09-13
- Primary completion
- 2026-09-13
- Completion
- 2026-09-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GT201 | Cell therapy | 5e+09 cells | — |
| Subject | GT201 | Cell therapy | 1e+10 cells | — |
| Subject | GT201 | Cell therapy | 5e+10 cells | — |